Contineum Therapeutics Inc

CTNMNASDAQ · USD
9.67USD0.00 (-1.93%)
325

Contineum Therapeutics Inc (CTNM) Covered Calls

Contineum Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 30.95%, average versus the past year. CTNM's highest covered call setup is the $15.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 52.13% out of the money with 35 days to expiration, a 53.14% return until expiration, and a 554.22% theoretical annualized return. Across the setups shown, annualized returns run from 132.65% to 554.22% at strikes between $12.50 and $22.50, with 35 to 245 days to expiration, as of Nov 13, 2026.

Read more

Running CTNM covered calls helps you generate income from Contineum Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CTNM covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CTNM stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CTNM covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CTNM covered call is worth writing.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

2026-12-183515.0052.130.100.55524.0053.14554.22-1.01+0.194,9750.45
2027-04-1615422.50128.190.104.901274.00129.21306.24-1.01+0.4814.80
2026-12-183512.5026.770.104.10274.0027.79289.80-1.01+0.52284.00
2027-04-1615420.00102.840.104.901024.00103.85246.15-1.01+0.491,0004.80
2027-06-1721622.50128.190.104.901274.00129.21218.34-1.01+0.4814.80
2027-07-1624522.50128.190.604.901324.00134.28200.05-6.09+0.5104.30
2027-06-1721620.00102.840.104.901024.00103.85175.49-1.01+0.4914.80
2027-04-1615415.0052.131.452.75659.0066.84158.41-14.71+0.4941.30
2027-07-1624520.00102.840.104.901024.00103.85154.72-1.01+0.4904.80
2027-06-1721617.5077.480.104.90774.0078.50132.65-1.01+0.5104.80

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank30.95% Moderate
  • Market cap (M$)380
  • 52 weeks high-45.61%
  • 52 weeks low43.90%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$21.43
    121.61% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-03
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.77
  • EPS growth next 5 years2.24%

As of Nov 16, 2026